Research Topics
Genomes and Genes | Gerold BeplerSummaryAffiliation: H. Lee Moffitt Cancer Center and Research Institute Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancerGerold Bepler
Program and Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
J Thorac Oncol 3:1112-8. 2008..The goal was to achieve a disease response rate of 50% and to determine if the expression levels of genes associated with GP metabolism are predictive of response...
Molecular analysis-based treatment strategies for non-small cell lung cancerGerold Bepler
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Cancer Control 15:130-9. 2008..Improved understanding in the molecular biology and genetics of lung cancer has resulted in the identification of individual genes, gene expression profiles, and molecular pathways that may be useful for clinical management decisions...- Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720Gerold Bepler
Program and Divison of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, USA
Clin Lung Cancer 8:509-11. 2007 - Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition)Jhanelle Gray
Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, MRC 4W, Room 4046, Tampa, FL 33612, USA
Chest 132:56S-68S. 2007..Chemoprevention is the use of specific agents to reverse, suppress, or prevent the process of carcinogenesis. This article reviews the major agents that have been studied for chemoprevention... - RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancerGerold Bepler
H Lee Moffitt Cancer Center and Research Institute, MRC 4W, Room 4046, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
J Clin Oncol 24:4731-7. 2006..However, the principal hypothesis that intratumoral levels of gene expression are associated with disease response has not been addressed... - Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancerGeorge Simon
Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
J Clin Oncol 25:2741-6. 2007..We hypothesized that selection of double-agent chemotherapy based on tumoral RRM1 and ERCC1 expression would be feasible and beneficial for patients with advanced NSCLC... 
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancerZhong Zheng
Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
Cancer 112:2765-73. 2008..We hypothesized that intratumoral TS expression would be prognostic of outcome in stage I NSCLC...- Setting the stage for tailored chemotherapy in the management of non-small cell lung cancerGeorge R Simon
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC 4W, Tampa, FL 33612, USA
Future Oncol 4:51-9. 2008.... - Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancerAlberto A Chiappori
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
J Thorac Oncol 5:484-90. 2010..Our aim was to determine the expression levels of these proteins to assess their potential clinical utility in SCLC... - Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerEric B Haura
Department of Thoracic Oncology and Biostatistics, Clinical Trials and Clinical Pharmacology Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
J Clin Oncol 28:1387-94. 2010.... - Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancerTawee Tanvetyanon
Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
J Clin Oncol 26:4610-6. 2008.... - Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancerGerold Bepler
Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
J Thorac Oncol 6:553-8. 2011..A reduction in both local and distant recurrence is needed to improve patients' outcome. Performing molecular studies on serially collected tumor specimens may result in a better selection of therapeutic options... - DNA synthesis and repair genes RRM1 and ERCC1 in lung cancerZhong Zheng
From the Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
N Engl J Med 356:800-8. 2007..RRM1, the regulatory subunit of ribonucleotide reductase, is involved in carcinogenesis, tumor progression, and the response of non-small-cell lung cancer to treatment... - EGR1 predicts PTEN and survival in patients with non-small-cell lung cancerBernadette Ferraro
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, MRC3 E, Room 3056, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
J Clin Oncol 23:1921-6. 2005..For these reasons, we hypothesized that reduced levels of EGR1 would correlate with inferior outcome in patients with NSCLC... - Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancerAlberto Chiappori
Thoracic Oncology Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Oncology 68:382-90. 2005..Despite the use of novel chemotherapeutic agents, patients with advanced non-small cell lung cancer (NSCLC) continue to show a poor survival... - Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Cancer 112:2021-9. 2008..The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS)... - Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancerAlberto A Chiappori
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Clin Cancer Res 14:1464-9. 2008..This study was designed to assess the influence of atrasentan on paclitaxel pharmacokinetics and to determine the safety and efficacy of atrasentan in combination with paclitaxel-carboplatin... - ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signalingSmitha Pillai
H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
Mol Cell Biol 31:3052-67. 2011.... - Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancersTawee Tanvetyanon
Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
J Thorac Oncol 5:1018-24. 2010..For those undergoing surgery, limited information exists on the relationship between tumor size and survival... - Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancerEric B Haura
Thoracic Oncology Program and Biostatistics Core, The H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
Clin Cancer Res 11:8288-94. 2005..We evaluated Stat3 activation in early stage non-small cell lung cancers (NSCLC) and how this relates to upstream epidermal growth factor receptor (EGFR) activation, tumor apoptosis, and prognosis... - Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevanceGerold Bepler
Thoracic Oncology Program, Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
Lung Cancer 47:183-92. 2005..We conclude that clinical studies using RR37 and RR524 for decisions on chemotherapy are premature and that further functional studies on the RRM1 promoter are required to fully elucidate factors controlling RRM1 expression... - Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to realityGeorge R Simon
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Int J Biochem Cell Biol 39:1318-28. 2007..This approach is currently being validated in a prospective phase III trial. In the future, assessment of NER function may play a central role in NSCLC treatment decision making... - Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cellsJingchun Gao
Department of Experimental Therapeutics and Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
Cancer Biol Ther 8:1671-9. 2009..These results suggest that Mirk is overexpressed in lung cancer, acts as a survival factor in lung cancer cells and may be a novel therapeutic target... - Using translational research to tailor the use of chemotherapy in the treatment of NSCLCGerold Bepler
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
Lung Cancer 50:S13-4. 2005..The discovery of prognostic molecular markers, such as the putative suppressor gene (RRM1), represents a novel and potential parameter to help guide clinical treatment decisions... - Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancerAlberto Chiappori
H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
J Thorac Oncol 5:369-75. 2010..We examined the efficacy of enzastaurin plus pemetrexed as second-line therapy in patients with advanced (stage IIIA/B or IV) non-small cell lung cancer in a double-blinded, randomized, phase II study... - Neoadjuvant chemotherapy for resectable non-small-cell lung cancerJhanelle Gray
University of South Florida, Tampa, FL, USA
Oncology (Williston Park) 23:879-86. 2009..To clarify these issues, well-structured phase III trials comparing adjuvant to neoadjuvant chemotherapy are needed... - Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancerNithya Ramnath
H. Lee Moffitt Cancer Center and Research Institute, Thoracic Oncology Program, Tampa, FL 33612, USA
Chest 128:3467-74. 2005..However, it appears to be less efficacious in terms of radiographic and pathologic response rates compared with platinum-containing chemotherapy doublets... - Pharmacogenomics: a reality or still a promise?Gerold Bepler
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Lung Cancer 54:S3-7. 2006.... - Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokersJhanelle E Gray
Moffitt Cancer Center, Tampa, FL, USA
Cancer 119:1023-32. 2013..The authors of this report evaluated enzastaurin, a selective protein kinase C-β (PKC-β) inhibitor with antiproliferative and proapoptotic properties, in former smokers... - ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancerGeorge R Simon
Thoracic Oncology Program and Experimental Therapeutics Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Ste 3170, Tampa FL 33612, USA
Chest 127:978-83. 2005..We therefore evaluated the effect of intratumoral ERCC1 expression on survival in non-small cell lung cancer (NSCLC) patients who underwent surgical resection for cure... - Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon
Thoracic Oncology Program, H Lee Moffitt Cancer Center Research Institute, Tampa, FL 33612, USA
Cancer Control 10:388-95. 2003..We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor... - Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysisTawee Tanvetyanon
Biostatistics Division, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33613, USA
J Clin Oncol 26:1142-7. 2008..However, some suggest that the survival outcome among patients with a synchronous metastasis is poor. It remains unclear whether this treatment approach is warranted among those with synchronous metastasis... - Molecular predictors of chemotherapy response in non-small-cell lung cancerJhanelle Gray
H Lee Moffitt Cancer Center and Research Institute, Division of Thoracic Oncology, Tampa, Florida 33612, USA
Expert Rev Anticancer Ther 7:545-9. 2007..Recently, how these genes affect lung cancer therapy has been explored in the clinical setting with the goal of finding customized treatment algorithms to optimize efficacy, improve outcomes and minimize toxicity... - RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancerGerold Bepler
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
J Clin Oncol 22:1878-85. 2004..It is located in a region of loss of heterozygosity in non-small-cell lung cancer (NSCLC), which is a predictor of poor survival. We hypothesized that RRM1 expression would be a significant predictor of outcome in NSCLC... - A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancerTawee Tanvetyanon
H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
J Thorac Oncol 2:1091-7. 2007..We evaluated available literatures to summarize the state of current knowledge and provide suggestions for future studies... - Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancerZhong Zheng
Thoracic Oncology Program, The H. Lee Moffitt Cancer Center and Research Institute, MRC3 East, Room 3056, 12902 Magnolia Drive, Tampa, FL 33612-9497, USA
Chest 128:308-16. 2005..Targeting EGFR may therefore have more promise in chemoprevention or in patients with smaller early-stage NSCLCs compared with those with more advanced disease... - Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cellsLei Wang
Department of Pathology and Cell Biology, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America
PLoS ONE 7:e44265. 2012..In summary, our findings suggest that HDAC6 is positively associated with cisplatin resistance in NSCLC and reveal HDAC6 as a potential novel therapeutic target for platinum refractory NSCLC... - Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNETMarilyn M Bui
Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL 33612 9497, USA
Fetal Pediatr Pathol 29:385-92. 2010..High TS1 expression, not RRM1 and ERCC1, was associated with long overall survival (p value = 0.057). Thus in-situ TS1 protein expression in Ewing/PNET is a prognostic marker... - Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brandsTawee Tanvetyanon
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa FL 33612, USA
Cancer 113:150-7. 2008..In the current study, the authors investigated the risk of lung cancer associated with beta-carotene in smokers or former smokers and surveyed the beta-carotene content in national brand multivitamins... - Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancerScott J Antonia
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Clin Cancer Res 12:878-87. 2006..CONCLUSIONS: This study provides clinical support for an emerging paradigm in cancer immunotherapy, wherein optimal use of vaccination might be more effective, not as a separate modality, but in direct combination with chemotherapy... - Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lungLuke T Nordquist
H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Suite 3170, Tampa, FL 33612, USA
Chest 126:347-51. 2004.... - Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductaseAshish Gautam
Division and Program of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
Cancer Res 66:6497-502. 2006..We conclude that the regulatory subunit of ribonucleotide reductase has tumor suppressor activity that is mediated through efficient DNA damage repair... - Physician referral for fertility preservation in oncology patients: a national study of practice behaviorsGwendolyn P Quinn
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
J Clin Oncol 27:5952-7. 2009..This study examined the referral practices of oncologists in the United States... - Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesionsTeresita Munoz-Antonia
Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
Cancer 110:1527-31. 2007..The authors previously observed that, in head and neck squamous cell carcinoma, the expression of the TGFbeta type II receptor (TbetaR-II) decreases as tumors become less differentiated and more biologically aggressive... - Malignant pleural mesothelioma: a comprehensive reviewRoohi Ismail-Khan
Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Cancer Control 13:255-63. 2006..In patients with advanced disease, several newer antitumor agents are already showing a capability of extending survival so it is not unreasonable to expect further progress in this area... - Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategiesEric B Haura
Thoracic Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Clin Lung Cancer 6:113-22. 2004.... - Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatmentNagi B Kumar
Department of Population Sciences, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA
Curr Treat Options Oncol 11:107-17. 2010.... - Lung cancer patients' decisions about clinical trials and the theory of planned behaviorGwendolyn P Quinn
Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA
J Cancer Educ 26:641-8. 2011..Results indicate that the theory of planned behavior may be a useful tool to examine psychosocial needs in relation to behavioral intention of clinical trial participation... - Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006Benjamin Djulbegovic
H Lee Moffitt Cancer Center, 12902 Magnolia Dr, MRC, Room 2067H, Tampa, FL 33612, USA
Arch Intern Med 168:632-42. 2008..We assessed how often experimental cancer treatments that undergo testing in randomized clinical trials (RCTs) result in discovery of successful new interventions... - Patient-provider communication and perspectives on smoking cessation and relapse in the oncology settingVani Nath Simmons
Moffitt Cancer Center, Department of Health Outcomes and Behavior, Tampa, USA
Patient Educ Couns 77:398-403. 2009..To fill a gap in research by examining cancer patient-provider communication regarding tobacco use and patients' perspectives regarding their experiences with smoking cessation and relapse... - Proteomic contributions to personalized cancer careJohn M Koomen
H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
Mol Cell Proteomics 7:1780-94. 2008.... - A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocationDonghwa Kim
Departments of Molecular Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
J Biol Chem 285:8383-94. 2010.... - Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon
Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Clin Cancer Res 12:4645-51. 2006..In phase I studies with oral CI-1033, dose-limiting toxicities were primarily gastrointestinal, supporting the exploration of i.v. dosing to achieve optimal drug exposures by increasing bioavailability... - Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell linesJun Zhou
Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
J Nucleic Acids 2010:597098. 2010..The impact of p53 mutations in patients treated with gemcitabine should be studied in prospective clinical trials to develop a model with improved precision of predicting drug efficacy... - A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chestGerold Bepler
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
Cancer Control 10:306-14. 2003..Computed tomography (CT) screening of the chest has shown promise for early detection of lung cancer, but evidence for a reduction in lung cancer mortality by CT screening is not available... - Lung cancer. Practice organizationW Michael Alberts
H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
Chest 123:332S-337S. 2003..Treatment recommendations should be based on locally agreed-on adaptations of clinical practice guidelines. Provisions for ongoing care should be apparent to all concerned.. - The guinea pig syndrome: improving clinical trial participation among thoracic patientsGwendolyn P Quinn
Division and Program of Thoracic Oncology, H L Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
J Thorac Oncol 2:191-6. 2007.... - RRM1-induced metastasis suppression through PTEN-regulated pathwaysAshish Gautam
Lung Cancer Program, Roswell Park Cancer Institute, Buffalo, New York, USA
Oncogene 22:2135-42. 2003..Increased PTEN expression was required for the RRM1-induced suppression of cell motility and FAK phosphorylation. We conclude that RRM1 functions as a metastasis suppressor gene through induction of PTEN expression... - Regular aspirin use and lung cancer riskKirsten B Moysich
Roswell Park Cancer Institute, Buffalo, NY, USA
BMC Cancer 2:31. 2002.... - Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancerRafael Rosell
Department of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Oncogene 22:3548-53. 2003..The predictive value of beta-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival... - Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancerDong Feng Tan
Lung Cancer Program, Roswell Park Cancer Institute, State University of New York, Buffalo, New York 14263, USA
Anticancer Res 23:1665-72. 2003..This information may also potentially serve as a tool for clinical decision-making when selecting patients for adjuvant treatments of NSCLC... - Prognostic significance of gelsolin expression level and variability in non-small cell lung cancerJun Yang
Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Lung Cancer 46:29-42. 2004..The present study used immunohistochemistry to evaluate the prognostic effect of gelsolin expression in 155 patients with resectable NSCLC... - Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancerGerold Bepler
Lung Cancer Program, Roswell Park Cancer Institute, Buffalo, NY, USA
J Clin Oncol 20:1353-60. 2002..NSCLC frequently manifests loss of heterozygosity (LOH) at chromosome segment 11p15.5. Whether LOH at 11p15.5 is an independent prognostic variable has yet to be determined... - Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancerIbrahim S Aljada
Roswell Park Cancer Institute, State University of New York, Buffalo, Elm and Carlton Sts, Buffalo, NY 14263, USA
J Clin Oncol 22:3218-29. 2004..Thus, TIMP-1 overexpression may serve to help identify patients with particularly aggressive disease for adjuvant treatments. In addition, the TIMP-1 molecule may represent a novel therapeutic target for treatment of some NSCLCs... - Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patientsRafael Rosell
Medical Oncology Service, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
Clin Cancer Res 10:1318-25. 2004..Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity... - Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancerYun Oh
Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 26:1135-41. 2008..This phase II trial of enzastaurin was conducted to determine the 6-month progression-free survival (PFS) rate in advanced, metastatic NSCLC... - Interpretation of genetic risk feedback among African American smokers with low socioeconomic statusIsaac M Lipkus
Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, NC 27701, USA
Health Psychol 23:178-88. 2004..The authors suggest additional research is needed to develop more effective strategies for communicating genetic risk feedback to motivate smoking cessation... - Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancerBrandon A Howard
Department of Radiology, Duke University, Durham, NC, USA
Lung Cancer 46:313-23. 2004..While both proteins considered in this study were overexpressed in the vast majority of NSCLCs, they were not found to be of prognostic significance... - Non-small cell lung cancerDavid S Ettinger
J Natl Compr Canc Netw 6:228-69. 2008 - Targeted therapy in combination with gemcitabine in non-small cell lung cancerRafael Rosell
Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Semin Oncol 30:19-25. 2003..Preliminary findings that a subset of gemcitabine/cisplatin-treated patients with low ERCC1 and RRM1 mRNA levels show a significantly longer survival and highlight the possibilities of individually tailored chemotherapy... - Southern Blotting of genomic DNA from lung and its tumors. Application to analysis of allele loss on chromosome 11p15.5Diana M Pitterle
Department of Surgery, University of Wisconsin-Madison Medical School, Madison, WI, USA
Methods Mol Med 75:263-77. 2003 - Lung cancer: provoking new concepts, generating novel ideas, and rekindling enthusiasmGerold Bepler
Cancer Control 10:275-6. 2003 - Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low incomeColleen M McBride
Duke Comprehensive Cancer Center, Duke Department of Community and Family Medicine, Chapel Hill, North Carolina 27710 2949, USA
Cancer Epidemiol Biomarkers Prev 11:521-8. 2002.... - Statins and lung cancer riskJhanelle Gray
Chest 131:1274-5. 2007 - Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumabJhanelle Gray
Department of Thoracic Oncology, Yale New Haven Medical Center, New Haven, Connecticut, USA
J Thorac Oncol 2:571-3. 2007..In this report, we present the first known case of visceral perforation in a patient with metastatic non-small cell lung cancer after treatment with bevacizumab... - Obtaining DNA from a geographically dispersed cohort of current and former smokers: use of mail-based mouthwash collection and monetary incentivesJoseph E Bauer
Department of Health Behavior, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Nicotine Tob Res 6:439-46. 2004..This pilot study showed that this requirement could pose some challenges in population-based research... - Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemiaScott N Freeman
J Natl Cancer Inst 97:1088-9; author reply 1093-5. 2005 - Reported cessation advice given to African Americans by health care providers in a community health clinicKathryn I Pollak
Duke Comprehensive Cancer Center, Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, NC 27710 2949, USA
J Community Health 27:381-93. 2002..Providers may need additional training and prompting to counsel young healthy smokers about the importance of cessation... - The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomesSuzanne C O'Neill
Social and Behavioral Research Branch, NHGRI NIH, Bethesda, Maryland 20892, USA
Genet Med 10:121-30. 2008..Outcomes include proportion who logged on to the study website to consider testing, made informed decisions to log on and to be tested... - Non-small cell lung cancer clinical practice guidelines in oncologyDavid S Ettinger
J Natl Compr Canc Netw 4:548-82. 2006
Research Grants
- Exisulind for Chemoprevention of Lung CancerGerold Bepler; Fiscal Year: 2007..The data generated by these investigations will be important for future decisions on large-scale chemoprevention trials using disease incidence and mortality as endpoints. ..
- RRM1/PTEN Axis in Non-Small Cell Lung CancerGerold Bepler; Fiscal Year: 2007..The purpose of this application is to corroborate this hypothesis in a prospective phase II clinical trial with gemcitabine-based chemotherapy and radiation in patients with locally advanced inoperable stage III NSCLC. ..
- Pharmacogenomics of Neoadjuvant Gemcitabine-Pemetrexed *Gerold Bepler; Fiscal Year: 2006....
- RRM1 in the Management of Lung CancerGerold Bepler; Fiscal Year: 2009....